Season 4 - Ep2: Lp(a) and aortic valve stenosis - The truth about climate change and heart disease

15 snips

Feb 5, 2026

Guest

Hugh Montgomery

Hugh Montgomery, intensive care medicine chair focused on climate and health. JP Carpenter, cardiology commentator who summarizes recent studies. Borge Nordestgaard, cardiology professor known for Lp(a) research. They discuss Lp(a) links to aortic valve stenosis and emerging RNA therapies. They cover climate change’s immediate threats to cardiovascular health and practical mitigation and adaptation steps clinicians can take.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Lp(a) Strongly Linked To Aortic Stenosis

High Lp(a) is causally linked to a broad range of vascular diseases, including myocardial infarction and ischemic stroke.
Aortic valve stenosis shows an especially strong association with high Lp(a), even stronger than for myocardial infarction.

INSIGHT

Mechanism Remains Speculative

The mechanism linking Lp(a) to valve disease is not settled and remains speculative.
Nordestgaard suggests Apo(a) may impair fibrinolysis and promote thrombus accumulation on valves.

ADVICE

Screen Lp(a) In Early Valve Disease

Measure Lp(a) in patients with early or emerging aortic stenosis to identify causal drivers.
Follow these patients more closely with echocardiography and consider future Lp(a)-lowering therapies.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
Lp(a) and aortic valve stenosis
The truth about climate change and heart disease
Snapshots

Host: Emer Joyce

Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach

Want to watch that episode? Go to: https://esc365.escardio.org/event/2548

Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview

Disclaimer:

ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

All declarations of interest are listed at the end of the episode.

The ESC is not liable for any translated content of this video. The English language always prevails.

Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.

Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change.

Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.